M-106
Mycophenolic acid solution
1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
grade
certified reference material
Quality Segment
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in acetonitrile
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−70°C
SMILES string
COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O
InChI
1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
InChI key
HPNSFSBZBAHARI-RUDMXATFSA-N
Gene Information
human ... IMPDH1(3614), IMPDH2(3615)
General description
Assayed in therapeutic drug monitoring to ensure patients remain within the drug′s therapeutic range, mycophenolic acid is an immunosuppressant drug and the active metabolite of the prodrug mycophenolate mofetil. This analytical standard is suitable for LC-MS/MS applications including therapeutic drug monitoring and other clinical or diagnostic applications.
Preparation Note
This product contains an ampule of 1 mL, at a concentration of 1.0 mg/mL in acetonitrile.
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Supply conditions do not apply to the regions and states of Brazil: North, Northeast, Mato Grosso do Sul, Mato Grosso, and Rio Grande do Sul.
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2 - Flam. Liq. 2
저장 등급
3 - Flammable liquids
wgk
WGK 2
flash_point_f
35.6 °F - closed cup
flash_point_c
2 °C - closed cup
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
CD25 blockade for refractory polymyositis.
Nicolò Pipitone et al.
Clinical and experimental rheumatology, 31(3), 474-474 (2013-03-08)
Mycophenolate mofetil in severe lupus nephritis: should post hoc analyses change treatment patterns?
Jonathan J Hogan et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 61(5), 692-693 (2013-04-16)
David Wofsy et al.
Arthritis and rheumatism, 65(6), 1586-1591 (2013-03-27)
Clinical trials of therapies for lupus nephritis have used many different primary outcome measures, ranging from complete response to time to end-stage renal disease. The objective of this study was to compare several possible outcome measures, using data from a